Login to Your Account



Ziopharm Adds $50M, Pushing Internal, Partnered Programs

By Jennifer Boggs
Managing Editor

Monday, January 23, 2012
Taking advantage of a modest stock bump following its presentation at the J.P. Morgan Healthcare Conference earlier this month, Ziopharm Oncology Inc. priced a $50.2 million public offering to support ongoing work with late-stage programs, including palifosfamide and a DNA therapeutic gained via last year's partnership with Intrexon Corp.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription